作者
Juliet Carmichael,Ines Figueiredo,Bora Gürel,Nick Beije,Wei Yuan,Jan Rekowski,George Seed,Suzanne Carreira,Claudia Bertan,Maria de los Dolores Fenor de la Maza,Khobe Chandran,Antje Neeb,Jon Welti,Lewis Gallagher,Denisa Bogdan,Mateus Crespo,Ruth Riisnaes,Ana Ferreira,Susana Miranda,Jinqiu Lu,Michael M. Shen,Emma Hall,Núria Porta,Daniel Westaby,Christina Guo,Rafael Grochot,Christopher J. Lord,Joaquín Mateo,Adam Sharp,Johann S. de Bono
摘要
BACKGROUND. Clinical trials have suggested antitumor activity from PARP inhibition beyond homologous recombination deficiency (HRD). RNASEH2B loss is unrelated to HRD and preclinically sensitizes to PARP inhibition. The current study reports on RNASEH2B protein loss in advanced prostate cancer and its association with RB1 protein loss, clinical outcome and clonal dynamics during treatment with PARP inhibition in a prospective clinical trial.
寻道图强
shinysparrow
爱静静
YifanWang
sutharsons
浅尝离白
Singularity
贰鸟
TrucCSC
随机子
共享精神
Magali
70
从容芮
穆紫
樱桃猴子
慕青
lanxinyue
丘比特
杳鸢
皖公网安备34019202002308
